$3.40
1.04% today
Nasdaq, Feb 05, 04:19 pm CET
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Arbutus Biopharma Corporation Stock price

$3.36
+0.09 2.75% 1M
-0.26 7.18% 6M
+0.09 2.75% YTD
+1.00 42.37% 1Y
+0.34 11.26% 3Y
+0.55 19.57% 5Y
-19.83 85.51% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.08 2.44%
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Key metrics

Market capitalization $636.69m
Enterprise Value $515.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 76.51
P/S ratio (TTM) P/S ratio 94.46
P/B ratio (TTM) P/B ratio 5.95
Revenue growth (TTM) Revenue growth -69.69%
Revenue (TTM) Revenue $6.74m
EBIT (operating result TTM) EBIT $-78.55m
Free Cash Flow (TTM) Free Cash Flow $-70.63m
Cash position $127.79m
EPS (TTM) EPS $-0.43
P/E forward negative
P/S forward 102.90
EV/Sales forward 83.34
Short interest 4.44%
Show more

Is Arbutus Biopharma Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Arbutus Biopharma Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Arbutus Biopharma Corporation forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Arbutus Biopharma Corporation forecast:

Buy
80%
Hold
20%

Financial data from Arbutus Biopharma Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
6.74 6.74
70% 70%
100%
- Direct Costs 1.41 1.41
4% 4%
21%
5.34 5.34
74% 74%
79%
- Selling and Administrative Expenses 20 20
4% 4%
292%
- Research and Development Expense 63 63
21% 21%
932%
-77 -77
0% 0%
-1,145%
- Depreciation and Amortization 1.41 1.41
4% 4%
21%
EBIT (Operating Income) EBIT -79 -79
0% 0%
-1,165%
Net Profit -77 -77
2% 2%
-1,138%

In millions USD.

Don't miss a Thing! We will send you all news about Arbutus Biopharma Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arbutus Biopharma Corporation Stock News

Positive
Seeking Alpha
6 days ago
Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 vaccine technology.
Neutral
GlobeNewsWire
23 days ago
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon
Positive
Seeking Alpha
29 days ago
Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-101, with preliminary data expected in the first half of 2025. The global Hepatitis B Virus market size is anticipated to reach $6.65 billion by 2034.
More Arbutus Biopharma Corporation News

Company Profile

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Head office Canada
CEO Michael McElhaugh
Employees 73
Founded 2005
Website www.arbutusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today